biostudies-literatureBarwatt JNIAID NIH HHSFoundation for the National Institutes of Healthe0013248https://www.ebi.ac.uk/biostudies/studies/S-EPMC12342302biostudies-literatureUnknown19(8)<h4>Background</h4>Several antigen-detection assays have been developed for the rapid diagnosis of talaromycosis, but their utility has been limited by a lack of commercial options. The aim of this study was to perform a head-to-head comparison of the performance of our in-house monoclonal antibody-based Mp1p antigen-detecting enzyme immunoassay (EIA) with its recently-developed commercial platform.<h4>Methods</h4>In this diagnostic accuracy, retrospective, case-cohort study, we compared the sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-) of the commercial Wantai Mp1p EIA versus our in-house Mp1p EIA on paired plasma and urine samples from 424 hospitalized adults with advanced HIV disease, including 224 cases of proven talaromycosis, where TalaPLoS neglected tropical diseasesComparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.PMC12342302U01AI169358R01 AI143409U01 AI169358R01AI143409Cai JPBrown LVenugopalan SLy VTChan JFHoa NTLe TYuen KYThu NTMBarwatt JSambath HNGonzalez PfalseComparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.<h4>Background</h4>Several antigen-detection assays have been developed for the rapid diagnosis of talaromycosis, but their utility has been limited by a lack of commercial options. The aim of this study was to perform a head-to-head comparison of the performance of our in-house monoclonal antibody-based Mp1p antigen-detecting enzyme immunoassay (EIA) with its recently-developed commercial platform.<h4>Methods</h4>In this diagnostic accuracy, retrospective, case-cohort study, we compared the sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-) of the commercial Wantai Mp1p EIA versus our in-house Mp1p EIA on paired plasma and urine samples from 424 hospitalized adults with advanced HIV disease, including 224 cases of proven talaromycosis, where Tala2025-01-01T00:00:00Z2025 Aug2026-05-04T22:01:41.98Z2026-04-07T21:00:55.899ZS-EPMC123423024074902410.1371/journal.pntd.0013248